Unlabelled: Santiago Roth was a Swiss fossil finder, naturalist, and paleontologist that emigrated to Argentina in 1866. His work largely influenced the discipline in the country at the end of the twentieth century, particularly the stratigraphy of the Pampean region. Some of his collections of Pampean fossils were sold to museums and private collectors in Europe and were accompanied by elaborated catalogues. Fossils in the Roth's catalogues N° 2 and 3 are housed today in the Natural History Museum of Denmark, fossils from catalogues N° 4 to 6, were sold to Swiss museums, with Catalogue N° 5 currently housed at the Department of Paleontology, Universität Zürich. Here, we provide a general framework on the stratigraphy from the Roth's Pampean fossil sites, summarize the history of the Pampean fossils in Europe originally collected by Roth, and provide historical and curatorial details of the Roth's collection at the Department of Paleontology, Universität Zürich.
Supplementary Information: The online version contains supplementary material available at 10.1186/s13358-023-00283-5.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542304 | PMC |
| http://dx.doi.org/10.1186/s13358-023-00283-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Nature
November 2024
Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
Article Synopsis
- Researchers studied strokes from 1990 to 2021 to understand how many people get them and how they are affected around the world.
- In 2021, strokes caused about 7.3 million deaths and were a major cause of health problems, especially in specific regions like Southeast Asia and Oceania.
- There are differences in stroke risks based on where people live and their age, and some areas actually saw more strokes happening since 2015.
Performance comparison of a previously validated microhaplotype panel and a forensic STR panel for DNA mixture analysis.
Forensic Sci Int Genet
January 2025
Forensic Genetics Unit, Institute of Forensic Sciences, Universidade de Santiago de Compostela, Spain. Electronic address:
Short Tandem Repeats (STRs) are the most widespread markers in forensic genetics. However, STR stutter peaks can mask alleles from a minor contributor when analysing mixtures, hindering the interpretation of complex profiles. In this study we compared the performance of a previously described panel of microhaplotypes (MHs), an alternative type of forensic marker, against a standard STR kit.
View Article and Find Full Text PDFDemonstrating Agreement between Radio and Fluorescence Measurements of the Depth of Maximum of Extensive Air Showers at the Pierre Auger Observatory.
Phys Rev Lett
January 2024
Center for Astrophysics and Cosmology (CAC), University of Nova Gorica, Nova Gorica, Slovenia.
We show, for the first time, radio measurements of the depth of shower maximum (X_{max}) of air showers induced by cosmic rays that are compared to measurements of the established fluorescence method at the same location. Using measurements at the Pierre Auger Observatory we show full compatibility between our radio and the previously published fluorescence dataset, and between a subset of air showers observed simultaneously with both radio and fluorescence techniques, a measurement setup unique to the Pierre Auger Observatory. Furthermore, we show radio X_{max} resolution as a function of energy and demonstrate the ability to make competitive high-resolution X_{max} measurements with even a sparse radio array.
View Article and Find Full Text PDFSafety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Lancet HIV
February 2024
MSD France, Puteaux, France. Electronic address:
Background: In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies.
Methods: DRIVE-FORWARD and DRIVE-AHEAD are multicentre, double-blind, randomised, active comparator-controlled, phase 3 trials of first-line antiretroviral treatment in adults with HIV-1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!